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Abstract 
 
Purpose: The study purpose was to define changes in coagulation across the sepsis spectrum using 
rotational thromboelastometry (ROTEM). 
Methods: Sepsis patients were recruited on admission to the Emergency Department and Intensive 
Care Units of a large teaching hospital in Wales. ROTEM markers of clot development and fibrinolysis 
were determined, as well as standard coagulation markers. A healthy control group matched for age 
and gender was also recruited (n = 44).  
Results: 100 patients were recruited (50 sepsis, 20 severe sepsis and 30 septic shock). Maximum clot 
firmness was significantly higher in the sepsis (p < 0.001) and severe sepsis (p = 0.012) groups than 
the healthy control (71.6 ± 4.5 and 70.4 ± 4.1 vs 64.4 respectively). In septic shock there was 
prolonged clot development; however, maximum clot firmness remained normal. Fibrinolytic 
function was significantly impaired in septic shock, which was also significantly associated with 28-
day mortality (p < 0.001).  
Conclusions: ROTEM indicated significantly enhanced clot structural development in sepsis and 
severe sepsis, which could be indicative of a hypercoagulable phase. In septic shock, despite there 
being a prolongation of clotting pathways and impaired fibrinolysis, clot mass was comparably 
normal, suggestive of the development of a clot with healthy characteristics.  
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Introduction 
 
Sepsis is known to exert a complex effect on the coagulation system, globally affecting all aspects of 
clot formation, namely kinetic activity, clot development and fibrinolysis [1, 2]. It is critically 
important for the clinician to know how the underlying pathophysiological progression of sepsis 
affects the coagulation system in order to deliver and target appropriate therapy. Clinically, it is well 
recognised that the earlier phases of sepsis induce a hypercoagulable state, but in septic shock, 
there still remains uncertainty on how the underlying pathophysiology affects the coagulation 
profile, and eventual clot formation, particularly the effects on clot structural development.  
The hypercoagulable effect of sepsis leads to increased thromboembolic risk [3], but this is 
not detected by standard markers of coagulation [4]. Due to the limitations of conventional tests 
such as PT and aPTT, and the need for a dynamic, sensitive maker of coagulation, point of care tests 
of coagulation are increasingly utilised in the clinical setting [4]. Rotational Thromboelastometry 
(ROTEM) is a viscoelastic point of care test and provides bedside information on both clot structural 
development and fibrinolytic function. ROTEM can be performed using blood which has been 
activated through the extrinsic pathway (EXTEM test) or the intrinsic pathway (INTEM test). Whereas 
standard markers focus on the kinetics of coagulation, or concentration of individual components, 
ROTEM provides a global picture of the coagulation status of patients and their overall effect on clot 
outcome at point of care. ROTEM has the advantage that it is a point of care test, and not only gives 
the global effects of kinetic coagulation activity and fibrinolysis but also has the added advantage of 
being able to determine clot quality and mass. Therefore more recently studies have utilised either 
ROTEM or thromboelastography (TEG) as an improved measurement to quantify the effect of sepsis 
progression on coagulation in the various stages of severity [5–13]. 
These studies have utilised several parameters of the global test as a main outcome in 
treatment as well as assessing disease severity and outcome. One of the main parameters utilised to 
assess thrombogenicity has been maximum clot firmness (MCF) which is known to be a marker of 
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clot development and mass in sepsis and other disease states. Increased clot mass is indicative of a 
hypercoagulable state, whereas reduced clot mass and firmness is indicative of a hypocoagulable 
state [14] and is also associated with poor outcomes [7]. Although previous studies have looked at 
the different sepsis stages in isolation or comparatively, no previous study has assessed how 
progressive pathophysiological change across the sepsis spectrum affects the coagulation profile 
using ROTEM. In this prospective observational study ROTEM was used to determine global 
coagulation change across all stages of sepsis and compared to conventional markers of coagulation 
in patients presenting to the emergency department. All of these were compared against a healthy 
matched control independently.  
Some of the data related to the research in this manuscript was presented and published as 
an abstract in the International Symposium of Intensive Care and Emergency Medicine 2016 prior to 
the completion of this study [15, 16]. 
 
Material and Methods 
 
Ethical Approval 
Full ethical approval was given by the South West Wales Research Ethics Committee. Informed 2-
stage written consent was given by patients with capacity to do so. Assent was obtained from 
personal or legal representation in cases where capacity to give informed consent was lacking.  
 
Recruitment of Subjects with Sepsis 
Subjects that met sepsis criteria as outlined by the American College of Chest Physicians/Society of 
Critical Care Medicine in 1991 [17] were recruited to this study within 24 hours of admission. 
Patients on any medication likely to affect coagulation such as any anticoagulant, antiplatelet or 
blood component replacement therapy were excluded. Patients with any history of disease that 
affects the coagulation profile (malignancy, renal failure, liver disease, thromboembolic disease) 
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were excluded. Patients that were deemed insensitive to include i.e. impending death were also 
excluded from the study. 
 At the time of recruitment, patients were categorised as sepsis, severe sepsis or septic 
shock. Categorisation was blinded, and carried out by an intensive care specialist independent of the 
study. Definitions were followed as outlined by the American College of Chest Physicians / Society of 
Critical Care Medicine in 1991.[17] Sepsis was defined as two or more of the SIRS criteria, with 
evidence of infection, severe sepsis was defined as sepsis with acute organ dysfunction of at least 
one organ and septic shock was defined as sepsis with perfusion abnormality (lactate > 2 mmol/L) 
and refractory hypotension in the absence of cardiogenic shock or bleeding. All patients were 
defined at point of entry. 
 A group of healthy volunteers matched for age, gender and from a demographically similar 
population group was recruited as a healthy control. 
 
Blood Sampling 
Blood was sampled at the time of inclusion to the study, and the first 5mls of blood was always 
discarded. Blood was drawn into 3.2% sodium citrate vacutainers (Greiner Bio-One GmbH, Austria, 
REF: 454327) to assess standard coagulation markers (aPTT, PT, Fibrinogen) and ROTEM 
thromboelastometry. A further blood sample was drawn into EDTA vacutainers (Becton, Dickinson 
and Company, UK, REF: 367839) to assess platelet count, white blood count and haemoglobin. 
 
Laboratory Markers 
Standard coagulation markers (aPTT (instrinsic), PT (extrinsic) and fibrinogen) were determined using 
a Sysmex CA1500 automated analyser and platelet count, white blood count and haemoglobin was 
determined using a Sysmex XE 2100 automated haematology analyser. All samples were analysed 
within 2 hours of collection. 
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Rotational Thromboelastometry 
Thromboelastometry was performed using a ROTEM delta whole blood haemostasis system. Blood 
coagulation was assessed with ROTEM by both intrinsic (INTEM) and extrinsic (EXTEM) activation. 
Tests were carried out in accordance with the manufacturer’s recommendations using disposable 
cups and pins (Cup and pin pro, Tem Innovations GmbH, Martin-Kollar-Str, Germany, REF: 200011). 
The automated pipetting system was used to recalcify and activate the blood with the appropriate 
reagents for each test. 20µl CaCl2 0.2M, STARTEM reagent (Tem innovations GmbH, Munich, 
Germany, REF: 503-10) and 20µl thromboplastin-phospholipid INTEM reagent (Tem innovations 
GmbH, Munich, Germany, REF: 503-02) were added to 300µL of blood for the INTEM test. 20µL CaCl2 
0.2M STARTEM reagent and 20µL tissue factor EXTEM reagent (Tem innovations GmbH, Munich, 
Germany, REF: 503-05) were added to 300µL blood for the EXTEM test. The Clotting Time (CT), 
Maximum Clot Firmness (MCF) and Lysis Index at 60 minutes (LI60) were recorded to assess the 
kinetic, structural and fibrinolytic aspects of clot development. 
 
Statistical Analysis 
All statistical analysis was carried out on IBM Statistical Package for Social Sciences (SPSS) for 
Windows, version 22.0 (Armonk, NY: IBM Corp.). Values are reported as mean and standard 
deviation or median and interquartile range where appropriate. Pearson’s chi-squared test was used 
to assess differences in the frequency distribution of nominal parameters across groups. Students T-
test was used to assess differences between two normally distributed groups whereas Kruskal-Wallis 
was used to determine differences between two non-normally distributed groups. One-way ANOVA 
was used to assess differences in normally distributed data between more than two groups, and 
Kruskal-Wallis was used to assess differences between more than two non-normally distributed 
groups. Data normality was assessed using Shapiro-Wilk test with an α value of 0.05. Bonferroni 
corrected posthoc analysis was used to assess multiple comparisons across groups. 
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Results 
 
Patient Characteristics 
100 sepsis patients in total were included in the study. This included 50 patients with sepsis, 20 with 
severe sepsis and 30 with septic shock. The screening  44 healthy volunteers matched for gender and 
age were also recruited as a healthy control group. Patient groups were matched for age, gender 
and source of infection. SOFA score, hospital length of mortality and 28 day mortality were all 
significantly increased with increasing severity of group (p < 0.05). Information on patient 
characteristic and demographics can be found in Table 1. 
 
Changes in Standard Markers of Coagulation 
The results of the standard markers of coagulation are shown in Table 2. Performing multiple 
comparison tests using Bonferroni corrected post hoc analysis we found that standard kinetic 
markers of coagulation PT and aPTT were significantly prolonged in septic shock (p < 0.001) when 
compared to all other groups. PT was also significantly prolonged in severe sepsis compared to the 
healthy group (p < 0.005). An increased fibrinogen concentration was observed in sepsis and severe 
sepsis (p < 0.001) consistent with the underlying inflammatory response of the disease process. In 
the septic shock group, although fibrinogen concentration was significantly lower than in sepsis (p < 
0.01), it remained significantly higher than in the healthy group (p < 0.05). A significantly reduced 
platelet count was observed in patients with septic shock compared to all other groups (p<0.05). 
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Haemoglobin was significantly lower in the septic shock group when compared to all other groups (p 
< 0.05). The healthy value of haemoglobin was significantly increased when compared to the sepsis 
and severe sepsis groups (p < 0.05). A significantly different White blood count was observed for the 
healthy patients when compared to all stages of sepsis (p<0.001), however, no significant differences 
were observed between the different sepsis groups. We found that the healthy group had a 
significantly higher value of haemoglobin than the sepsis groups (p<0.001) and the sepsis and severe 
sepsis groups had significantly higher values than the septic shock group (p<0.01). We found no 
significant difference between the C-reactive protein results between the sepsis groups.  
 
Changes in Thromboelastometry Measurements (ROTEM) across the Sepsis Spectrum 
Baseline ROTEM measurements CT, MCF and LI60 are shown in Figure 1. A significant trend towards 
prolongation of EXTEM clotting time (CT) was observed with increasing severity of stage (p<0.001). 
Overall a hypercoagulable effect was observed in sepsis and severe sepsis, with a significant increase 
in the clot firmness and rate of formation. Furthermore, EXTEM clot formation time (CFT) was 
significantly shortened in the sepsis group compared to the healthy control (62.5 ± 15.3 vs 81.8 ± 
18.3 (p = 0.004)). In septic shock, ROTEM measurements indicated normal but delayed clot 
formation and significantly impaired fibrinolysis (p < 0.001). 
 
 
Comparison between Survivors and non-Survivors at 28 Days 
All patients were followed up for all cause 28-day mortality. Characteristics of survivors and non-
survivors at 28 days are shown in Table 3. A significant trend towards hypocoagulability was 
observed in non-survivors compared to survivors.  Poor outcome was also associated with prolonged 
EXTEM CT and impaired fibrinolysis, as indicated by significantly increased LI60. Structural ROTEM 
parameters (MCF, α) were not significantly different in patients that did not survive 28 days. 
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Discussion 
 
In this study for the first time several ROTEM parameters were determined against severity of stage 
of sepsis across the whole sepsis spectrum as a diagnostic test in the emergency setting at time of 
presentation. In this single study we demonstrated that in the earlier stages of sepsis progression 
(sepsis and severe sepsis), ROTEM was more sensitive in detecting a hypercoagulable phase when 
compared to standard markers of coagulation, indicating enhanced clot development in sepsis and 
severe sepsis when compared to the standard healthy control group and normal ROTEM ranges. 
These findings provide more evidence that a clear hypercoagulable state is associated with sepsis, 
with increased clot mass and viscoelasticity (MCF), as has been shown in previous studies [1, 18, 19]. 
Although there was no change in the initial time to clot formation (CT), the clot formation time (CFT) 
remained shortened in the earlier stages of sepsis indicating enhanced clot mass formation, 
suggesting altered mechanical clot properties. These findings were also reflected by a rapid increase 
in clot mass development, as measured by the α angle, and higher resultant MCF possibly indicative 
of the hypercoagulable phase and potential thromboembolic risk in the earlier stages of sepsis and 
severe sepsis as noted in previous studies [3]. In the later stage of septic shock both the CT and CFT 
were prolonged, indicative of a hypocoagulable phase. However, despite a prolongation of the time 
based ROTEM markers, both the alpha angle and MCF remained within the normal range in septic 
shock, indicating normal clot development and mass as indicated by all structural markers of ROTEM 
thromboelastometry. This is indicative of a normally formed clot in septic shock, despite there being 
significant alterations in clotting time and fibrinolysis and is in contrast to recent studies which have 
specifically measured new markers of clot elasticity and strength [19]. These studies have shown 
that clot strength was significantly weakened when going from severe sepsis to the septic shock 
phase which was thought to be due to the effect on the mechanical strength by alteration of the 
cross-linked fabric leading to a looser, weaker clot. Furthermore, an increase in kinetic time in septic 
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shock was mirrored by increases in the aPTT and PT, both of which were prolonged. Although 
ROTEM parameters in the earlier phases of sepsis indicated a hypercoagulable effect with increased 
clot mass, surprisingly there was no change in clot formation or clot mass in the septic shock group, 
despite a profound effect of a decrease in the kinetic activity of clot formation. This may be partly 
explained by there being an elevated fibrinogen concentration and a normal platelet count.   
 Markers of fibrinolysis remained unchanged in the earlier phases of sepsis, but there was 
pronounced fibrinolytic activity and impaired fibrinolytic function in the septic shock group as 
measured by D-dimers and LI60 respectively. Although fibrinolytic function was impaired, D-dimer 
concentration indicated an increase in the fibrinolytic activity in septic shock. This suggests the 
ongoing intravascular fibrin formation (consumption), which could contribute to the impairment of 
the fibrinolytic and procoagulant systems. Previous studies have suggested that fibrinolysis is 
regulated in part by clot structure [20, 21], with denser, more elastic clots being more difficult to 
lyse. However, the results herein do not support this, as ROTEM indicated impaired fibrinolysis in 
weaker clots associated with septic shock. This again suggests the overall effects on coagulation 
could possibly be due to the overall consumption of procoagulant and fibrinolytic proteins that 
inevitably increases with increasing severity of sepsis, leading to an overall impairment of both clot 
development and breakdown. It has been shown previously that fibrinolytic shutdown is also 
significantly associated with increased mortality in trauma patients, highlighting the complexity of 
coagulation in critical illness.[22] 
Previous studies have attempted to investigate this impairment of fibrinolysis in septic shock 
by measuring individual concentrations of fibrinolytic proteins in sepsis, and found that a reduced 
plasminogen concentration was present in patients with severe sepsis/septic shock [2]. Furthermore, 
studies have shown there is a reduced tPA and PAI-1 concentration [23, 24, 25], which would 
suggest the fibrinolytic system is progressively overloaded as activation of the coagulation system is 
enhanced, which could help to explain the underlying development of DIC in sepsis. These 
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mechanisms could help to explain the progressively increased risk of both bleeding and thrombosis 
that are observed with increasing severity of sepsis. 
In this study ROTEM gave some understanding and new information in profiling in the earlier 
stages of sepsis, indicating a hypercoagulable phase, but there was no consistent marker to indicate 
the progression from the early stages from sepsis to septic shock. Although ROTEM gave us some 
information regarding the kinetic information (time-based markers) and clot rigidity, ROTEM does 
not provide a measurement of elasticity, and even Newtonian fluids have been shown to provide 
substantial readings using thromboelastographic techniques [26]. 
 Although ROTEM has been utilised in the diagnosis of haemorrhage blood loss and 
component replacement in major haemorrhage associated with surgery [27–29] or trauma [30, 31], 
no studies have yet determined its usage as a marker of hyper and hypocoagulable states in patients 
attending the emergency department who were subsequently admitted to the ward or ICU. 
Although ROTEM determined a hypercoagulable phase indicative of an increased clot mass in sepsis, 
it did not differentiate between or show major change in clot mass in those patients that presented 
with septic shock. What remains uncertain is why ROTEM defines patients in septic shock still 
produce a normal profile of a clot. It may be that the measurement of clot development and 
strength is in mm, which is an arbitrary description, and not an exact scientific marker of elasticity or 
true clot strength.  
Further larger studies are required to ascertain the potential clinical utility of ROTEM within 
the emergency setting. Although ROTEM shows a normal MCF trace in septic shock, this may not 
reflect accurately the viscoelastic change, as determined previously. Further work is needed to 
determine the role that sepsis plays in altering the viscoelastic profile and its relationship to disease 
severity and its effect on clot quality. There may very well be a discrepancy between clot mass, as 
measured by ROTEM and final clot strength in terms of its elastic mechanical properties, which 
warrants further studies to determine this relationship. 
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Study Limitations 
As with other similar studies involving critically ill patients, this study has a number of limitations. It 
is difficult to account for comorbidities between the groups, and there could also be differences in 
concomitant medications. In an attempt to address this, strict inclusion/exclusion criteria were 
adopted. Furthermore, although several results were significant, this study was not powered for 
outcome. 
 
Conclusions 
ROTEM indicated enhanced clot mass and development in sepsis and severe sepsis, consistent with a 
hypercoagulable phase and increased thrombotic risk. However, in septic shock, despite 
prolongation of laboratory markers and clotting time, ROTEM indicated a normal clot mass and 
development consistent with a normocoagulable state. Despite the development of a normal clot 
mass in septic shock, ROTEM indicated an impairment of fibrinolysis, which could potentially lead to 
increased thrombotic risk, despite the lack of a perceived hypercoagulable state. 
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Tables 
Table 1: Baseline characteristics of healthy volunteers and sepsis patients 
  Healthy  Sepsis  
Severe 
Sepsis  
Septic Shock  
Significance 
Value 
N 44 50 20 30   
Age (years)  60.8 ± 18.6  59.6 ± 19.8  66.3 ± 17.4  
66.6 ± 14.9 
0.268 
  
Male Gender 
(n[%]) 
22 [50]  24 [48]  9 [45]  18 [60]  0.693 
Source of 
Infection 
    
0.398 
 
        Respiratory - 29 [58] 12 [60] 11 [37]  
        Urinary Tract - 8 [16] 4 [20] 7 [23]  
        Abdominal - 9 [18] 1 [5] 9 [30]  
        Soft Tissue - 2 [4] 1 [5] 0 [0]  
         Other - 2 [4] 2 [10] 3 [10]  
SOFA Score - 3 (1, 3.5)  5 (4, 6)  9.5 (6.75, 12) <0.001 
Hospital Length 
of Stay (days) 
- 6 (2, 9) 9 (5, 18)  15 (4, 38) 0.006 
28 Day Mortality 
(n [%]) 
- 1 [2]  3 [15] 13 [43] <0.001 
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Table 2: Changes in standard markers of coagulation and ROTEM parameters (CFT and Aplha 
Angle) across the sepsis spectrum. Standard laboratory markers of coagulation and ROTEM 
parameters  are shown for the different sepsis groups. Data presented as mean ± SD. Significance 
values indicated (One-way ANOVA). 
  Healthy Sepsis Severe Sepsis Septic Shock 
Significance 
Value 
PT (sec) 10.5 ± 0.6 11.0 ± 1.0 11.5 ± 1.2 13.3 ± 2.3 <0.001 
aPTT (sec) 25.4 ± 2.0 26.6 ± 3.1 29.1 ± 6.7 35.6 ± 8.9 <0.001 
Fibrinogen 
(g/L) 
3.1 ± 0.5 4.6 ± 0.6 4.5 ± 1.0 3.7 ± 1.6 <0.001 
Platelets 
(x109/L)* 
231 (205, 
299) 
245  (221,   
334) 
234 (185,    
337) 
155 (102,    249) <0.001 
White Blood 
Count 
(x109/L)* 
6.7 (5.1, 7.9) 
18.0  (14.4,  
21.4) 
17.5 (10.6,    
19.8) 
11.4 (7.3,  22.1) <0.001 
CRP (mg/dL) - 
79 (39.5, 
221.5)  
193 (124, 422) 
127.5 (21.0, 
127.5) 
0.078 
Haemoglobin 
(g/dL)* 
14.1 
(13.4,15.0)   
12.7 (11.9, 
14.6) 
12.3 (12.3, 
13.6) 
10.6 (9.1, 11.6) <0.001 
ROTEM 
EXTEM 
          
CFT (sec) 80 (69, 96) 61 (51, 75) 66 (56, 73) 85 (67, 103) <0.001 
Aplha (°) 77 (71, 79) 78 (76, 80)  77 (76, 79) 75 (70, 76) <0.001 
ROTEM 
INTEM 
          
CFT (sec) 64 (57, 77) 58 (48, 63) 58 (56, 67) 73 (59, 89) <0.001 
Aplha (°) 77 (74, 78) 78 (77, 81) 78 (77, 78) 75 (72, 79) <0.001 
*not normally distributed represented as a median and interquartile range) 
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Table 3: Comparison of ROTEM parameters in survivors and non-survivors. ROTEM parameters in 
sepsis patients that survived and did not survive 28 days are shown. Data presented as mean ± SD, 
median (IQR). Comparisons made using students t-test or Kruskal-Wallis test, with respective 
significant values indicated. 
 
ROTEM EXTEM 
Survived (n=83) Died (n=17) Significance Value 
CT (sec)* 62.0 (53.2,  70.5) 75.5 (58.3,  101.0) 0.032 
MCF (mm) 69.6 ± 7.0 63.9 ±13.5 0.215 
Alpha (°)* 55.00  (31.0, 64.00) 66.5 (38, 78.5) 0.228 
LI60 (%)* 94 (90.25, 96) 95.5 (92.5, 98)  <0.001 
ROTEM INTEM    
CT (sec)* 156.0 (137.0,  189.5) 178.0   (135.3, 210.3) 0.623 
MCF (mm) 69.1 ± 7.2 64.8 ± 14.3 0.405 
Alpha (°)* 60.0  (50,  67.5) 66.0  (55.0, 116.3) 0.305 
LI60 (%)* 94 (90, 96) 96 (94.75, 98) <0.001 
*not normally distributed represented as a median and interquartile range) 
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Figure Legend. 
 
 
Figure 1: Changes in the different ROTEM parameters across the sepsis spectrum. ROTEM markers 
of coagulation across the sepsis and in the healthy control group are shown. Data presented as box 
plots (median and IQR) with whiskers representing the range. Healthy reference ranges as 
recommended by ROTEM are also shown on each graph respectively. Significant differences 
between groups assessed using Kruskal-Wallis test with multiple comparisons (Bonferroni 
correction). 
 
 
 
